2026/11/6 Announces Sep. 2026 Self-Assessed Revenue (Correction)

1.Date of occurrence of the event:2026/11/06

2.Company name:Gongwin Biopharm Holdings Co., Ltd.

3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office

4.Reciprocal shareholding ratios:N/A

5.Cause of occurrence:Correction to the Company's Unaudited Revenue for September 2026

6.Information items/ statements to be corrected: (1) Monthly Net Operating Revenue (2) Monthly Revenue Increase/Decrease (3) Monthly Revenue Change (%) (4) Year-to-Date Net Operating Revenue (5) Year-to-Date Revenue Increase/Decrease (6) Year-to-Date Revenue Change (%)

7.Amounts/ contents/ number of page to be corrected: (1) Sep. 2026 Monthly Net Revenue: NT$6,696K / US$210.78K (2) Sep. 2026 Monthly Revenue Increase: NT$1,646K / US$49.29K (3) Sep. 2026 Monthly Revenue Growth: 32.59% / 30.52% (4) Sep. 2026 YTD Net Revenue: NT$37,724K / US$1,188.25K (5) Sep. 2026 YTD Revenue Increase: NT$9,185K / US$280K (6) Sep. 2026 YTD Revenue Growth: 32.18% / 30.83%

8.Amounts/ contents/ number of page after correction: (1) Sep. 2026 Monthly Net Revenue: NT$2,897K / US$91.19K (2) Sep. 2026 Monthly Revenue Change: (NT$2,153K) / (US$70.30K) (3) Sep. 2026 Monthly Revenue Change: (42.63%) / (43.53%) (4) Sep. 2026 YTD Net Revenue: NT$33,925K / US$1,068.66K (5) Sep. 2026 YTD Revenue Increase: NT$5,386K / US$160.41K (6) Sep. 2026 YTD Revenue Growth: 18.87% / 17.66%

9.Countermeasures: Following the disclosure of a material announcement on the Market Observation Post System (MOPS), the announcement was republished.

10.Any other matters that need to be specified:None